Objectives
Hoarding Disorder, classified as a separate disorder in DSM-5, is a common, chronic, and potentially disabling syndrome that can be difficult to treat. Only one prior study prospectively measured response to pharmacotherapy in compulsive hoarders, finding that hoarders responded as well to paroxetine as did non-hoarding OCD patients. However, paroxetine was not tolerated well in that study, and overall response was moderate. Therefore, we conducted an open-label trial of venlafaxine extended-release for Hoarding Disorder.
Methods
24 patients meeting DSM-5 criteria for Hoarding Disorder were treated with venlafaxine extended-release for 12 weeks. All patients were free of psychotropic medications for at least 6 weeks prior to the study. No other psychotropic medications, cognitive-behavioral therapy, organizers, or cleaning crews were permitted during the study. To measure hoarding severity, the Saving Inventory-Revised (SI-R) and the UCLA Hoarding Severity Scale (UHSS) were administered before and after treatment.
Results
23 of the 24 patients completed treatment. Hoarding symptoms improved significantly, with a mean 36% decrease in UHSS scores and a mean 32% decrease in SI-R scores. Sixteen of the 23 completers (70%) were classified as responders to venlafaxine extended-release.
Conclusions
These results suggest that venlafaxine extended-release may be effective for treatment of Hoarding Disorder.